Liposomal anthracyclines for breast cancer

Seminars in Oncology

Volumn 28, Issue 4 SUPPL. 12, 2001, Pages 32-40

  Sparano, Joseph A ^a   Winer, Eric P ^a,b  

^a MONTEFIORE MEDICAL CENTER   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE DERIVATIVE; BLEOMYCIN; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DAUNORUBICIN; DEXAMETHASONE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; LIPOSOME; NAVELBINE; PACLITAXEL; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TRASTUZUMAB; VINCRISTINE;

ALOPECIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; BREAST CANCER; CARDIOTOXICITY; CLINICAL TRIAL; CONFERENCE PAPER; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG INDICATION; DRUG MEGADOSE; DRUG POTENTIATION; DRUG TISSUE LEVEL; FEBRILE NEUTROPENIA; HUMAN; KAPOSI SARCOMA; MONONUCLEAR PHAGOCYTE; MUCOSA INFLAMMATION; NAUSEA AND VOMITING; NEUROPATHY; PRIORITY JOURNAL; SKIN TOXICITY; STOMATITIS;

EID: 0034835602     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/sonc.2001.26436     Document Type: Conference Paper

References (55)

1. Treatment of metastatic disease: Hormonal and chemotherapy
2. Chemotherapy and survival in advanced breast cancer: The inclusion of doxorubicin in Cooper type regimens
3. Polychemotherapy for early breast cancer: An overview of the randomised trials
4. Docetaxel: A review of preclinical and clinical experience. Part 1: Clinical experience
5. Improved disease free and overall survival from the addition of sequential paclitaxel but not from the escalation of doxorubicin dose level in the adjuvant chemotherapy of patients with node-positive breast cancer
6. Delayed administration of dexrazoxane provides cardioprotection for patients with advanced breast cancer treated with doxorubicin-containing therapy
7. Negative staining of phospholipids and their structural modification by surface-active agents as observed in the electron microscope
8. Preclinical toxicology of liposome encapsulated doxorubicin (TLC D-99) comparison with doxorubicin and empty liposomes in mice and dogs
9. Comparison of the cardiotoxic effects of liposomal doxorubicin (TLC D-99) versus free doxorubicin in beagle dogs
10. Topoisomerase interactive agents
11. Therapy of primary and metastatic mouse mammary carcinoma with doxorubicin encapsulated in long circulating liposomes
12. Comparative study of the antitumor activity of free doxorubicin and polyethylene glycol-coated liposomal doxorubicin in a mouse lymphoma model
13. Doxorubicin encapsulated in sterically stabilized liposomes for the treatment of a brain tumor model: Biodistribution and therapeutic efficacy
14. Pharmacokinetics and therapeutics of sterically stabilized liposomes in mice bearing C-26 colon carcinoma
15. Tissue distribution and therapeutic effect of intravenous free or encapsulated liposomal doxorubicin on human prostate carcinoma xenografts
16. Therapy of human ovarian carcinoma xenografts using doxorubicin encapsulated in sterically stabilized liposomes
17. Arrest of human lung tumor xenograft growth in severe combined immunodeficient mice using doxorubicin encapsulated in sterically stabilized liposomes
18. In vitro and in vivo targeting of immunoliposomal doxorubicin to human B-cell lymphoma
19. The biodistribution and pharmacokinetics of stealth liposomes in patients with solid tumors
20. Population pharmacokinetics and pharmacodynamics of pegylated liposomal doxorubicin in patients with AIDS-related Kaposi's sarcoma
21. Doxorubicin encapsulated in liposome containing surface-bound polyethylene glycol: Pharmacokinetics, tumor localization, and safety in patients with AIDS-related Kaposi's sarcoma
22. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes
23. Selective delivery of doxorubicin to patients with breast carcinoma metastases by Stealth liposomes
24. Randomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin and vincristine in AIDS-related Kaposi's sarcoma
25. Pegylated liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of severe AIDS-related Kaposi's sarcoma: Results of a phase III clinical trial
26. Randomized comparative trial of liposomal doxorubicin versus bleomycin and vincristine in the treatment of AIDS-related Kaposi's sarcoma
27. Phase II study of liposomal doxorubicin (Doxil) in epithelial ovarian cancer: Antitumor activity and toxicity modification by liposomal encapsulation
28. Phase III study of TLC D-99 (liposome-encapsulated doxorubicin) vs. free doxorubicin in patients with metastatic breast cancer
29. A phase I-II study of intensive-dose adriamycin for advanced breast cancer
30. Phase II trial of high-dose liposome-encapsulated doxorubicin with granulocyte colony-stimulating factor in metastatic breast cancer
31. Phase II trial of liposome-encapsulated doxorubicin, cyclophosphamide, and fluorouracil as first-line therapy in patients with metastatic breast cancer
32. Reduced cardiotoxicity and preserved antitumor efficacy of liposome encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized multicenter trial of metastatic beast cancer
33. Phase III study of TLC D-99 plus cyclophosphamide vs. epirubicin plus cyclophosphamide in patients with metastatic breast cancer
34. A randomized phase II trial of Caetyx/Doxil versus doxorubicin in advanced or metastatic soft tissue sarcoma - An EORTC soft tissue and bone sarcoma (STBSG) trial
35. The use of cardiac biopsy to demonstrate reduced cardiotoxicity in AIDS Kaposi's sarcoma patients treated with pegylated liposomal doxorubicin
36. Phase II study of Doxil in doxorubicin-resistant metastatic breast cancer
37. EORTC 10968: Phase I study of Caelyx at a six week interval in patients with metastatic breast cancer
38. Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinoma
39. Treatment of advanced breast cancer with sterically stabilized liposomal doxorubicin: Results of a multicenter phase II trial
40. Doxil and intravenous cyclophosphamide as first-line therapy for patients with metastatic breast cancer: Interim results of an ongoing pilot trial
41. Phase I study of Doxil and vinorelbine in metastatic breast cancer
42. Phase I trial of Doxil plus vinorelbine in patients with advanced malignancies
43. Unexpected low efficacy of Caelyx and vinorelbine in metastatic breast cancer
44. Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: High antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study
45. Doxorubicin and paclitaxel, a highly active combination in the treatment of metastatic breast cancer
46. Phase II study results on safety and tolerability of Caelyx (Doxil) in combination with paclitaxel in the treatment of metastatic breast cancer
47. Phase I study of Doxil plus escalating doses of Taxol in the treatment of patients with advanced breast or gynecologic malignancies
48. Human pharmacokinetic characterization and in vitro study of the interaction between doxorubicin and paclitaxel in patients with breast cancer
49. Use of dexrazoxane and other strategies to prevent cardiomyopathy associated with doxorubicin-taxane combinations
50. Phase I trial of pegylated liposomal doxorubicin and docetaxel in advanced breast cancer
51. A phase I study of Taxotere and Doxil in patients with advanced malignancies
52. Phase I study of Doxil in combination with escalating doses of Taxotere in the treatment of patients with advanced malignancies
53. A phase I trial of liposomal doxorubicin (Doxil) given on day one followed by docetaxel (Taxotere) given on day five in patients with advanced solid tumors
54. Use of chemotherapy plus a monoclonal antibody HER2 for metastatic breast cancer that overexpressed HER2
55. Phase II randomized trial of doxorubicin plus paclitaxel (AT) versus doxorubicin HCL liposome injection (Doxil) plus paclitaxel (DT) in metastatic breast cancer